Available through MedReleaf's Concession
Scheme, doctors and patients will have more
freedom in choosing their cannabis medication
EDMONTON, AB, April 12,
2023 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:
ACB) (TSX: ACB), the Canadian company opening the world to
cannabis, and MedReleaf Australia today announced the launch of
IndiMed Tempo 26, a range of new higher THC dried cannabis products
for qualified patients under the MedReleaf Concession Scheme (MCS).
Tempo 26 will add to the portfolio of products available, giving
doctors the ability to prescribe from a wider range of options
for medical cannabis patients.
"We are proud to further expand the variety of high-quality
medical cannabis products that Australian patients can access
through the MedReleaf Concession Scheme, and with the addition of
Tempo 26, doctors and patients now have more control and choice
about their medical cannabis treatment than ever before," says
Miguel Martin, CEO of Aurora
Cannabis. "We are strongly committed to our patient-first approach
to cannabis and ensuring access to medical patients, in
Australia, and around the
world."
The MCS was developed by MedReleaf Australia and Aurora to
provide high-quality products and enhance patient access to medical
cannabis, which is not covered by the Pharmaceutical Benefits
Scheme (PBS). Through the MCS, patients can access compassionate
pricing, specifically for those with Pensioner Concession Cards,
Commonwealth Seniors Health Cards, Health Care Cards, and Veterans
Cards (DVA).
"Through the investment of Aurora and MedReleaf Australia, we
have been able to provide heavily discounted products via our
MedReleaf Concession Scheme, which widens the choice for
prescriptions and significantly improves access for disadvantaged
Australian patients struggling with debilitating health
conditions," says Russell Harding,
MedReleaf CEO. "These products are cultivated and manufactured in
Aurora's GMP accredited facilities and are made available for
doctors to prescribe via the TGA's Special Access Scheme."
Aurora currently holds a 10% ownership stake in MedReleaf
Australia, a fully licensed, private company. Together, they
provide Australian patients with several innovative, Aurora-branded
products, including dried flower, oils, soft gels, and resin
cartridges.
For further information about the MCS, doctors and health care
professionals can contact MedReleaf's clinical support team or
visit their website: www.medreleafaustralia.com.au.
About Aurora
Aurora is opening the world to cannabis, serving both the
medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Whistler, Being and Greybeard, as well
as CBD brands, Reliva and KG7. Medical cannabis brands include
MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co.
Aurora also has a controlling interest in Bevo Farms Ltd.,
North America's leading supplier
of propagated agricultural plants. Driven by science and
innovation, and with a focus on high-quality cannabis products,
Aurora's brands continue to break through as industry leaders in
the medical, performance, wellness and adult recreational markets
wherever they are launched. Learn more at www.auroramj.com and
follow us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
About MedReleaf
Australia
MedReleaf Australia is a private company established in 2016.
MedReleaf is licensed by the Australian Federal Government's Office
of Drug Control (ODC) to cultivate and manufacture medical
cannabis. MedReleaf also has licences to import, export and
wholesale medical cannabis. Its wholly owned subsidiary, MedReleaf
NZ, also has a Medicinal Cannabis Supply Licence issued by the New
Zealand Ministry of Health.
MedReleaf Australia is backed by more than 50 years of
pharmaceutical and healthcare expertise, is driven by Research and
Development, and has an exclusive strategic partnership with
Canada's Aurora Cannabis
Enterprises.
An asset-lean distinct business positioned to take advantage of
a rapidly growing markets built to service the Australian and
New Zealand medical industries
including doctors, pharmacists, and patients.
Forward Looking
Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, statements
regarding the launch of new and innovative products to the
Australian market through partnership with MedReleaf Australia,
leadership in the Australian market through that partnership, and
strategic international growth plans, including a commitment to the
Australian market.
.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in
developing forward-looking statements include, without limitation,
publicly available information from governmental sources as well as
from market research and industry analysis and on assumptions based
on data and knowledge of this industry which the Company believes
to be reasonable. Forward-looking statements are subject to a
variety of risks, uncertainties and other factors that management
believes to be relevant and reasonable in the circumstances could
cause actual events, results, level of activity, performance,
prospects, opportunities or achievements to differ materially from
those projected in the forward-looking statements. These risks
include, but are not limited to, the ability to retain key
personnel, the ability to continue investing in infrastructure to
support growth, the ability to obtain financing on acceptable
terms, the continued quality of our products, customer experience
and retention, the development of third party government and
non-government consumer sales channels, management's
estimates of consumer demand in Canada and in jurisdictions where the Company
exports, expectations of future results and expenses, the risk of
successful integration of acquired business and operations,
management's estimation that SG&A will grow only in proportion
of revenue growth, the ability to expand and maintain distribution
capabilities, the impact of competition, the general impact of
financial market conditions, the yield from cannabis growing
operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, including the current outbreak of
COVID-19, and other risks, uncertainties and factors set out under
the heading "Risk Factors" in the Company's annual information form
dated September 20, 2022 (the "AIF")
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com and filed
with and available on the SEC's website at www.sec.gov. The
Company cautions that the list of risks, uncertainties and other
factors described in the AIF is not exhaustive and other factors
could also adversely affect its results. Readers are urged to
consider the risks, uncertainties and assumptions carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on such information. The Company is under no
obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-and-medreleaf-australia-launch-indimed-tempo-26-further-strengthening-product-offerings-for-medical-cannabis-patients-301795410.html
SOURCE Aurora Cannabis Inc.